Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45
Status:
Recruiting
Trial end date:
2026-07-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about how a migraine prevention medicine works
for people who have migraines/headaches with their menstrual period. The study includes
people ages 18 to 45 who have been diagnosed with migraine and who have a migraine with their
menstrual period or those who have migraines with their menstrual period and at other times
of the month as well.
The main question the study aims to answer are:
• Does fremanazemab, an injectable calcitonin gene-related peptide (CGRP) pathway targeting
therapy, decrease migraines associated with menstruation?
Participants will
- have an evaluation and examination by a headache specialist physician
- will receive the study medicine or inactive substitute every three months for two
treatments
- fill out diaries about their migraines
- have tests on saliva to measure hormone levels
Researchers will compare the people who get the medicine to those who get the inactive
substitute to see if there are differences in response.